SpliSense is a clinical-stage biotech company developing inhaled antisense oligonucleotide therapies and a proprietary inhaled ASO platform designed to modulate gene expression and RNA processing in the lungs. Its lead program, SPL84, is an inhaled ASO therapy in clinical development for cystic fibrosis. The company is advancing a broader pipeline addressing cystic fibrosis, muco-obstructive lung diseases (including COPD, asthma and NCFB) and idiopathic pulmonary fibrosis. SpliSense is led by CEO Gili Hart and is based in Jerusalem, Israel. The recent financing of up to $13M, led by the Cystic Fibrosis Foundation, is earmarked to support continued clinical development of SPL84. The article does not report revenue, user metrics, prior rounds, or valuation information.

Total raised

$30M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2026